In a “rapid review” of Ivermectin for Covid-19 the South African National Department of Health recommended that eligible patients with Covid‐19 in South Africa should be considered for enrolment in relevant therapeutic trials, but did not endorse the drug for general treatment of Covid-19 patients.
“The evidence of efficacy and safety is very uncertain at this point. Early phase studies were of very low quality and do not demonstrate any clear evidence of efficacy or safety,” the committee wrote.
“Eligible patients with COVID‐19 in South Africa should be considered for enrolment in relevant therapeutic trials.”
Read the full report here